Targeting the CCL2/CCR2 has shown some promise in preclinical murine models of HCC, with the CCR2 antagonists, RDC018 and 747, exhibiting good efficacy in an orthotopic liver tumour model, significantly restricting tumour growth and metastasis [68,69]. Here, CCR2 is linked to neoplasm.